Radiopharm Theranostics L... (RADX)
5.40
-0.32 (-5.59%)
At close: Mar 25, 2025, 3:57 PM
5.06
-6.26%
Pre-market: Mar 26, 2025, 07:00 AM EDT
-5.59% (1D)
| Bid | 4.02 |
| Market Cap | 140.04K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -11.87 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.1 |
| Volume | 44,058 |
| Avg. Volume (20D) | 226,376 |
| Open | 5.99 |
| Previous Close | 5.72 |
| Day's Range | 5.40 - 6.00 |
| 52-Week Range | 3.55 - 50.82 |
| Beta | 0.89 |
About RADX
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical target...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol RADX
Analyst Forecast
According to 1 analyst ratings, the average rating for RADX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 177.78% from the latest price.
Stock Forecasts1 month ago
-4.29%
Radiopharm Theranostics shares are trading higher ...
Unlock content with
Pro Subscription
2 months ago
+32.75%
Radiopharm Theranostics shares are trading higher after the company announced it will execute a private placement and will raise $5 million in proceeds.